Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals

Thrombosis Research

Volumn 82, Issue 6, 1996, Pages 479-483

  Mhic Iomhair, Maura ^a   Lavelle, S M ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NONE

Author keywords

Aspirin; Dipyridamole; EACA; Ellagic acid; Heparin; Hypercoagulable

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; DIPYRIDAMOLE; ELLAGIC ACID; HEPARIN; KAOLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; HYPERCOAGULABILITY; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOGENICITY; VEIN THROMBOSIS;

EID: 0030585757     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00098-9     Document Type: Article

References (23)

1. 1 KARSKI J.M., TEASDALE S.J., NORMAN P.H., CARROLL J.A., WEISEL R.D., GLYNN M.F. Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J. Cardiothoracic Vasc. Anesth. 1993; 7: 431-435.
2. 2 DELROSSI A.J., CERNAIANU A.C., BOTROS S., LEMOLE G.M., MOORE R. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989; 96: 27-30.
3. 3 TRINH-DUC P., WINTREBERT P., BOULFOY D., ALBAT B., THEVENET A., ROQUEFEUIL B. Comparison of the effects of epsilon-aminocaproic acid and aprotinin on intra-and postoperative bleeding in heart surgery. Ann . Chirurgie. 1992; 46: 677-683.
4. 4 ZEIGLER Z.R. Effects of epsilon aminocaproic acid on primary haemostasis. Haemostasis 1991; 21: 313-320.
5. 5 LALWANI RB, STRICKER RB. Case report: successful use of antifibrinolytic therapy in acquired factor VIII deficiency. Am. J. Med. Sci. 1992; 303: 398-401.
6. 6 RATNOFF O.D., CRUM J.D. Activation of Hageman factor by solutions of ellagic acid. J. Lab. Clin. Med. 1961; 63: 359-377.
7. 7 GIROLAMI A., CLIFFTON E.E. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid. Thromb. et Diath. Haemorrh. 1967; 17: 165-175.
8. 8 HARA T., IWAMOTO M., ISHIHARI M., TOMIKAWA M. Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats. Haemostasis. 1994; 24: 351-357.
9. 9 MAC IOMHAIR MAURA, LAVELLE, S.M. Thrombus weight as a measure of hypercoagulability induced by drugs. Thrombos. Haemostas. 1979; 42: 1018-1021.
10. 10 LAVELLE S.M., MHIC IOMHAIR MAURA. Arterial thrombosis in rats by platinum wire insertions, ellagic acid and EACA. In: Breddin K., Zimmermann R. eds. Standardisation of animal models of thrombosis. Proc 17th Angiological Symposium Kitzbuhel 1983. F.K. Schattauer Verlag. Stuttgart, pp 157-160.
11. 11 LAVELLE S.M., MHIC IOMHAIR MAURA. The quantitative reduction by heparin of intravenous thrombosis in normal and hypercoagulable animals. Ir. J. Med. Sci. 1980; 149: 266-269.
12. 12 PENNER J.A. Hypercoagulation and thrombosis. Med. Clin. North Am. 1980; 64: 743-759.
13. 13 MENG K., O'DEA K. The protective effect of acetylsalicyclic acid on laser-induced venous thrombosis in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 283: 379-388.
14. 14 BOTTI R.E., RATNOFF O.D. Studies on the pathogenesis of thrombosis: an experimental "hypercoagulable" state induced by the intravenous injection of ellagic acid. J. Lab. Clin. Med. 1964; 64: 385-398.
15. 15 AGOSTINO D., CLIFFTON E.E. The effect of ellagic acid on traumatic bleeding in warfarin treated rats. Path. Europ. 1967; 2: 421-426.
16. 16 HARRIS W.H., SALZMAN E.W., ATHANASOULIS C.A., WALTMAN A.C., DE SANCTIS R.W. Aspirin prophylaxis of venous thromboembolism after total hip replacement. New Eng. J. Med. 1977; 297: 1246-1249.
17. 17 COEUGNIET E. Drugs with antithrombotic effect: experimental study. Thrombos. Haemostas. (Stuttg.) 1976; 35: 495-499.
18. 18 HONOUR AJ., HOCKADAY T.D.R., MANN J.I. The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels. Br. J. Exp. Pathol. 1977; 58: 268-272.
19. 19 GIROMINI M., BOUVIER C. A., DAMI R., DENIZOT M., JEANNET M. Effect of dipyridamole and aspirin in thrombotic microangiopathy. Br. Med. J. 1972; 1: 545-546.
20. 20 CHESEBRO J.H., FUSTER V., ELVEBACK L.R., McGOON D.C., PLUTH J.R., PUGA P.P., WALLACE R.B., DANIELSON G.K., ORSZULAC T.A., PIEHLER J.M., HARTZELL V.S. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am. J. Cardiol. 1983; 51:1537-1541.
21. 21 KLIMT CR., GENELL L. KNATTERUD, STAMLER J., FACC, MEIER P. Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol., 1986; 7: 251-269.
22. 22 PIRK J., VOJACEK J., KOVAK J., FABIAN J., FIRT P. Improved patency of the aortocoronary bypass by antithrombotic drugs. Ann. Thorac. Surg. 1986; 42: 312-314.
23. 23 VAIREL E.G., BOUTY-BOYE H., TOULEMONDE F., DOUTREMEPUICH C., MARSH N.A., GAFFNEY P.J. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway excercises a protective effect against thrombosis. Thromb. Res. 1983; 30: 219-224.